Drug shortage
Dofetilide Capsule · Pfizer Inc.
FDA drug shortage · To Be Discontinued · updated Apr 23, 2024
Key facts
| Generic name | Dofetilide Capsule |
|---|---|
| Proprietary name | Tikosyn |
| Company | Pfizer Inc. |
| Presentation | Tikosyn, Capsule, .125 mg (NDC 0069-5800-43) |
| Dosage form | Capsule |
| Strength | .125 mg |
| Status | To Be Discontinued |
| Therapeutic category | Cardiovascular |
| Package NDCs | 0069-5800-43 |
| First posted | Apr 23, 2024 |
| Last updated | Apr 23, 2024 |
| Discontinued | Apr 23, 2024 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: